iBio Inc (IBIO)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.72-8.44%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge iBio Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.08
Annual ending 2027-06-30
Revenue	—	16,667
EPS	—	-0.394
Annual ending 2028-06-30
Revenue	—	20,000
EPS	—	-0.59

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance clinical trial dosing in 2Q 2026	iBio plans to start clinical trial dosing in 2Q 2026.	Intact	Dosing not initiated by end of 2Q 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage operating losses and cash burn	The company aims to manage losses and cash burn while developing programs.	Broken	Operating loss exceeds negative $8.37 million in 2026-Q3	Operating income: $-16.383M FY2026-Q4; GAAP. Published target: Operating loss no worse than negative $8.37 million in 2026-Q3. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Source published Aug 28, 2026-16,383,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Operating loss increased from $18.6 million in 2025 to $35.1 million in 2026 fiscal year due to higher R&D spending, while cash and cash equivalents rose from $8.6 million to $56.4 million, reflecting successful financings. Management emphasizes disciplined financial execution; trajectory shows increased investment with strengthened balance sheet. Delivery assessment Oct 24, 2026
Stabilize and grow revenue after sharp decline	A primary condition in iBio Inc's published investment case. The stated target is Revenue decline less than 72% in next 12 months.	Intact	Revenue decline exceeds 72% in next 12 months	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-06-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue$0.00B

Unavailable → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 4
2026-07-25	Unavailable	Unavailable	2 / 4
2026-07-26	Unavailable	Unavailable	2 / 4
2026-07-27	Unavailable	Unavailable	2 / 4
2026-07-28	Unavailable	Unavailable	2 / 4
2026-07-29	Unavailable	Unavailable	2 / 4
2026-07-30	Unavailable	Unavailable	2 / 4
2026-07-31	Unavailable	Unavailable	2 / 4
2026-08-01	Unavailable	Unavailable	2 / 4
2026-08-02	Unavailable	Unavailable	2 / 4
2026-08-03	Unavailable	Unavailable	2 / 4
2026-08-04	Unavailable	Unavailable	2 / 4
2026-08-05	Unavailable	Unavailable	2 / 4
2026-08-06	Unavailable	Unavailable	2 / 4
2026-08-07	Unavailable	Unavailable	2 / 4
2026-08-08	Unavailable	Unavailable	2 / 4
2026-08-09	Unavailable	Unavailable	2 / 4
2026-08-10	Unavailable	Unavailable	2 / 4
2026-08-12	Unavailable	Unavailable	2 / 4
2026-08-13	Unavailable	Unavailable	2 / 4
2026-08-14	Unavailable	Unavailable	2 / 4
2026-08-15	Unavailable	Unavailable	2 / 4
2026-08-16	Unavailable	Unavailable	2 / 4
2026-08-17	Unavailable	Unavailable	2 / 4
2026-08-18	Unavailable	Unavailable	2 / 4
2026-08-19	Unavailable	Unavailable	2 / 4
2026-08-20	Unavailable	Unavailable	2 / 4
2026-08-21	Unavailable	Unavailable	2 / 4
2026-08-22	Unavailable	Unavailable	2 / 4
2026-08-23	Unavailable	Unavailable	2 / 4
2026-08-24	Unavailable	Unavailable	2 / 4
2026-08-25	Unavailable	Unavailable	2 / 4
2026-08-26	Unavailable	Unavailable	2 / 4
2026-08-27	Unavailable	Unavailable	2 / 4
2026-08-28	Unavailable	Unavailable	2 / 4
2026-08-29	Unavailable	Unavailable	2 / 4
2026-08-30	Unavailable	Unavailable	3 / 4
2026-08-31	Unavailable	Unavailable	3 / 4
2026-09-01	Unavailable	Unavailable	3 / 4
2026-09-02	Unavailable	Unavailable	3 / 4
2026-09-03	Unavailable	Unavailable	3 / 4
2026-09-04	Unavailable	Unavailable	3 / 4
2026-09-05	Unavailable	Unavailable	3 / 4
2026-09-06	Unavailable	Unavailable	3 / 4
2026-09-07	Unavailable	Unavailable	3 / 4
2026-09-08	Unavailable	Unavailable	3 / 4
2026-09-09	Unavailable	Unavailable	3 / 4
2026-09-10	Unavailable	Unavailable	3 / 4
2026-09-11	Unavailable	Unavailable	3 / 4
2026-09-12	Unavailable	Unavailable	3 / 4
2026-09-13	Unavailable	Unavailable	3 / 4
2026-09-14	Unavailable	Unavailable	3 / 4
2026-09-15	Unavailable	Unavailable	3 / 4
2026-09-16	Unavailable	Unavailable	3 / 4
2026-09-17	Unavailable	Unavailable	3 / 4
2026-09-18	Unavailable	Unavailable	3 / 4
2026-09-19	Unavailable	Unavailable	3 / 4
2026-09-20	Unavailable	$20,000	4 / 5
2026-09-21	Unavailable	$20,000	4 / 5
2026-09-22	Unavailable	$20,000	4 / 5
2026-09-23	Unavailable	$20,000	4 / 5
2026-09-24	Unavailable	$20,000	4 / 5
2026-09-25	Unavailable	$20,000	4 / 5
2026-09-26	Unavailable	$20,000	4 / 5
2026-09-27	Unavailable	$20,000	4 / 5
2026-09-28	Unavailable	$20,000	4 / 5
2026-09-29	Unavailable	$20,000	4 / 5
2026-09-30	Unavailable	$20,000	4 / 5
2026-10-01	Unavailable	$20,000	4 / 5
2026-10-02	Unavailable	$20,000	4 / 5
2026-10-03	Unavailable	$20,000	4 / 5
2026-10-04	Unavailable	$20,000	4 / 5
2026-10-05	Unavailable	$20,000	4 / 5
2026-10-06	Unavailable	$20,000	4 / 5
2026-10-07	Unavailable	$20,000	4 / 5
2026-10-08	Unavailable	$20,000	4 / 5
2026-10-09	Unavailable	$20,000	4 / 5
2026-10-10	Unavailable	$20,000	4 / 5
2026-10-11	Unavailable	$20,000	4 / 5
2026-10-12	Unavailable	$20,000	4 / 5
2026-10-13	Unavailable	$20,000	4 / 5
2026-10-14	Unavailable	$20,000	4 / 5
2026-10-15	Unavailable	$20,000	4 / 5
2026-10-16	Unavailable	$20,000	4 / 5
2026-10-17	Unavailable	$20,000	4 / 5
2026-10-18	Unavailable	$20,000	4 / 5
2026-10-19	Unavailable	$20,000	4 / 5
2026-10-20	Unavailable	$20,000	4 / 5
2026-10-21	Unavailable	$20,000	4 / 5
2026-10-22	Unavailable	$20,000	4 / 5
2026-10-23	Unavailable	$20,000	4 / 5
2026-10-24	Unavailable	$20,000	4 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	6	0	0
2026-06-01	8	0	0
2026-07-01	8	0	0
2026-08-01	8	0	0
2026-09-01	9	0	0
2026-10-01	9	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Advance clinical trial dosing in 2Q 2026Direct metric needs a verified mapping
Manage operating losses and cash burnPublished status: Broken
Stabilize and grow revenue after sharp declineDirect metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-76.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

iBio Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

IBIO is a high-risk clinical-stage biotechnology story, with value tied more to future program potential than current earnings. Its long-term thesis is in a watch state: development milestones are progressing, but recent financial performance is weak and management is rated volatile.

What's priced into iBio Inc

The valuation model has low confidence and points to a premium versus peers, while its expectations gap is near the top of the measured range. That combination suggests expectations may be demanding relative to the evidence, though the model attributes the difference to potential from the pipeline and reports low valuation fragility.

What the fundamentals likely do

Near term, the company remains loss-making, and its recent financial performance sits well below its industry cohort; a smaller-company, high-miss-rate profile also raises the chance of a weak report. Over the multi-year view, IBIO-600 dosing has broadly followed the stated plan, while IBIO-610 and IBIO-800 have advanced through earlier development stages, though execution and clinical outcomes remain uncertain.

What iBio Inc hinges on

The thesis depends on continued clinical progress, including planned IBIO-600 dose escalation and progress toward first-in-human testing for IBIO-610. A guidance cut would be a meaningful negative; broader Healthcare-sector strength could help sentiment, but that is a sector backdrop rather than proof of company progress.